Back to results
US 2008/0075694 A1Published application
MVA vaccine
OwnerIngo Drexler, Gerd Sutter +2inventors
InventorsIngo Drexler, Gerd Sutter, Georg Gasteiger, Volker Erfle
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a recombinant MVA, which carries a nucleic acid sequence coding for a fusion protein. The present invention is further directed to a kit of parts containing said recombinant MVA as well as to a method for enhancing T cell responses in a mammal.
Claims19
A kit of parts comprising the following components:
- a) a first component comprising one or more foreign proteins or a nucleic acid encoding same or functional parts thereof, which functional parts contain one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein;
- and
- b) a second component comprising a recombinant Modified Vaccinia Virus Ankara (MVA), which carries a nucleic acid sequence coding for a fusion protein comprising:
- Ubiquitin or a functional part thereof, which functional part contains one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein;
- and
- one or more foreign proteins, i.e. one or more proteins not naturally present as a part of MVA or functional parts thereof, which functional part contains one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein;
- wherein the first and second components optionally further comprise a pharmaceutically acceptable carrier.
4 more elements
Use of a recombinant MVA, which carries a nucleic acid sequence coding for a fusion protein comprising:
- Ubiquitin or a functional part thereof, which functional parts contain one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein;
- and
- one or more foreign proteins, i.e. one or more proteins not naturally present as a part of MVA or a functional part thereof, which functional part contains one or more substitutions, insertions and/or deletions when compared to the wild type protein whilst having the same function as the wild type protein,
- in anti-cancer therapy or in the prevention of infectious diseases as a boosting agent in prime-boost vaccinations.
1 more element
Dependencies are inferred from the claim text.